Analyzing Coeptis Therapeutics (COEP) & Its Peers

Coeptis Therapeutics (NASDAQ:COEP) is one of 284 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Coeptis Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Coeptis Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	0	1	0	3.00
Coeptis Therapeutics Competitors	1425	4556	11867	208	2.60

Coeptis Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 863.39%. As a group, “Biological products, except diagnostic” companies have a potential upside of 74.84%. Given Coeptis Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Coeptis Therapeutics is more favorable than its peers.

Institutional and Insider Ownership

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 50.5% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 21.5% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 15.9% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Coeptis Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-794.75%	-322.86%
Coeptis Therapeutics Competitors	-4,523.69%	-227.14%	-44.84%

Risk & Volatility

Coeptis Therapeutics has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ peers have a beta of 1.05, suggesting that their average share price is 5% more volatile than the S&P 500.

Earnings & Valuation

This table compares Coeptis Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coeptis Therapeutics	$80,000.00	-$21.27 million	-0.37
Coeptis Therapeutics Competitors	$554.66 million	-$33.50 million	6.60

Coeptis Therapeutics’ peers have higher revenue, but lower earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Coeptis Therapeutics peers beat Coeptis Therapeutics on 7 of the 13 factors compared.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.